Dethlefs Sven
Known title: EVP, North America CommercialCIK: 0001726010
Associated companies
this person other insiders at TEVA
Transaction History
| TEVA | ▼ Sell | Open Market | 58,066 | $547K | 3/7/2023 | View on chart |
| TEVA | ▼ Sell | Open Market | 19,355 | $192K | 3/6/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 24,952 | — | 3/5/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 38,538 | — | 3/4/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 13,931 | — | 3/4/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 17,346 | — | 2/28/2023 | View on chart |
| TEVA | ▼ Sell | Open Market | 17,346 | $171K | 2/28/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 42,309 | — | 2/28/2023 | View on chart |
| TEVA | ▼ Sell | Open Market | 42,309 | $418K | 2/28/2023 | View on chart |
| TEVA | ▼ Sell | Open Market | 6,993 | $52K | 3/7/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 24,952 | — | 3/5/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 37,939 | — | 3/4/2022 | View on chart |
| TEVA | ▼ Sell | Open Market | 3,904 | $29K | 3/4/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 13,930 | — | 3/4/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 17,346 | — | 2/28/2022 | View on chart |
| TEVA | ▼ Sell | Open Market | 4,862 | $40K | 2/28/2022 | View on chart |
| TEVA | ▼ Sell | Open Market | 4,138 | $37K | 2/9/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 13,135 | — | 2/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Teva Receives FDA Approval for Weltruza, Announces R&D Day
Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.
Teva Receives FDA Approval for Weltruza, Announces R&D Day. Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.